1. Home
  2. News Archive

More News

Expanded Use of Diabetic Donor Corneas May Help Address Tissue Shortages
Expanded Use of Diabetic Donor Corneas May Help Address Tissue Shortages

The growing prevalence of diabetes among cornea donors within the past decade has heightened concerns about the disease’s potential impact on keratoplasty outcomes and transplant success. Concern a...

Moria Highlights New CAIRS Instruments at 2026 EBAA Meeting
Moria Highlights New CAIRS Instruments at 2026 EBAA Meeting

Jana D’Amato Tothova, PhD, group R&D director at Moria, described for attendees of the “Innovative Solutions Showcase” at the 2026 EBAA meeting the benefits of Moria’s newly developed instruments d...

Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia
Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia

Everest Medicines, of Shanghai, China, has acquired rights in Greater China to Lenz Therapeutics’ Vizz (LNZ100) eye drops for presbyopia, Lenz reported June 7. Lenz, of San Diego, California, said ...

Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US
Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US

Bausch + Lomb reported May 19 that it had launched its PreserVision AREDS3 eye vitamins in the US for patients with age-related macular degeneration (AMD) at risk of progression. The supplements co...

Georgia Southern University Gains Funding for State’s First College of Optometry
Georgia Southern University Gains Funding for State’s First College of Optometry

Georgia Southern University announced May 26 that it had received $29.8 million in state funding to establish the first college of optometry in Georgia. The school said the money will support the r...

Clinical Trial Updates for Ophthalmic Candidates, June 2026
Clinical Trial Updates for Ophthalmic Candidates, June 2026

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Outlook Therapeutics Resubmits BLA for Lytenava After Winning FDA Appeal
Outlook Therapeutics Resubmits BLA for Lytenava After Winning FDA Appeal

Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...

Emerging Companies Pursuing Ophthalmic Indications, June 2026
Emerging Companies Pursuing Ophthalmic Indications, June 2026

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Poll of MDs, US Only, June 2026
Weekly Poll of MDs, US Only, June 2026

June 2026 Ophthalmic News Briefs
June 2026 Ophthalmic News Briefs

UK-based Rayner announced June 1 the launch of Ophteis Cohesive, a new OVD formulated with a high molecular weight to optimize space creation and ease of removal. Ophteis Cohesive is packaged at 1....

Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia
Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia

Everest Medicines, of Shanghai, China, has acquired rights in Greater China to Lenz Therapeutics’ Vizz (LNZ100) eye drops for presbyopia, Lenz reported June 7. Lenz, of San Diego, California, said ...

Formycon’s Aflibercept Biosimilar in Prefilled Syringes Now Available in EU
Formycon’s Aflibercept Biosimilar in Prefilled Syringes Now Available in EU

Germany’s Formycon announced May 19 that its aflibercept (Eylea) biosimilar, known in various territories as Ahzantive and Baiama, was now available in the European Union. It is being introduced in...

Samsung Bioepis Launches Aflibercept Biosimilar Branded Opuviz in EU
Samsung Bioepis Launches Aflibercept Biosimilar Branded Opuviz in EU

Korea’s Samsung Bioepis announced May 29 that it had launched Opuviz, a biosimiliar referencing Eylea (aflibercept), across Europe. The biosimilar is also available in Korea and Canada as Aflivu. H...

Harrow Relaunches Verkazia in the US for Vernal Keratoconjunctivitis
Harrow Relaunches Verkazia in the US for Vernal Keratoconjunctivitis

Harrow reported June 10 that it had relaunched Verkazia (cyclosporine ophthalmic emulsion, 0.1%) in the US for the treatment of vernal keratoconjunctivitis (VKC). VKC is a serious allergic eye dise...

AAO Licenses Clinical Practice Guidelines to OpenEvidence Chatbot for Doctors
AAO Licenses Clinical Practice Guidelines to OpenEvidence Chatbot for Doctors

The American Academy of Ophthalmology reported June 9 that it had licensed the guidance in itsPreferred Practice Patterns and Ophthalmic Technology Assessments to OpenEvidence for its medical AI pl...

Apotex Gains Health Canada Approval for Iheezo Ophthalmic Anesthesia
Apotex Gains Health Canada Approval for Iheezo Ophthalmic Anesthesia

Toronto’s Apotex announced May 26 that it had secured Health Canada marketing approval for Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a topical anesthetic indicated for ocular surface...

Bausch + Lomb Launches Blink Triple Care Preservative Free Drops in US
Bausch + Lomb Launches Blink Triple Care Preservative Free Drops in US

Bausch + Lomb announced June 1 the US launch of Blink Triple Care Preservative Free eye drops. The lipid- and water-based formula combines a natural oil—to help keep tears from evaporating too quic...

Lupin Gains US FDA Approval for Ranibizumab Biosimilar Branded Ranluspec
Lupin Gains US FDA Approval for Ranibizumab Biosimilar Branded Ranluspec

India’s Lupin Limited announced June 4 that the US FDA had approved Ranluspec (ranibizumab-hkdz) as an interchangeable biosimilar referencing Lucentis. Lupin said Ranluspec was the only interchange...

Alvotech Resubmits BLA to US FDA for Aflibercept Biosimilar
Alvotech Resubmits BLA to US FDA for Aflibercept Biosimilar

Alvotech, of Reykjavik, Iceland, reported June 4 that it had resubmitted its biologics license application (BLA) to the US FDA for AVT06, a biosimilar to Eylea (aflibercept). Alvotech said it had a...

Optos Names Alexandre Montague as CEO
Optos Names Alexandre Montague as CEO

UK-based Optos announced June 9 that it had appointed Alexandre Montague as chief executive officer, effective immediately. Optos, a subsidiary of Japan’s Nikon, pioneered ultra-widefield retinal i...

Oculis Scraps DME Eye Drop Program after Phase III Failure
Oculis Scraps DME Eye Drop Program after Phase III Failure

Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...

Outlook Therapeutics Resubmits BLA for Lytenava After Winning Appeal with FDA
Outlook Therapeutics Resubmits BLA for Lytenava After Winning Appeal with FDA

Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...

Rayner Launches New Ophteis Cohesive OVD, Rebrands Line
Rayner Launches New Ophteis Cohesive OVD, Rebrands Line

UK-based Rayner announced June 1 the launch of Ophteis Cohesive, a new ophthalmic viscosurgical device (OVD) developed and manufactured at its biomaterials facility in Portugal. The company said th...

Zeiss, M2care Invest in Maculaser, Developer of Temperature-Controlled Retinal Laser Therapy
Zeiss, M2care Invest in Maculaser, Developer of Temperature-Controlled Retinal Laser Therapy

Finland-based Maculaser Oy has received a new investment from Zeiss Ventures, the corporate venture capital arm of Germany’s Zeiss Group, and M2care, a European health tech venture studio, as Macul...

Sightpath to Deliver IQity’s Products Through Mobile Platform Under New Partnership
Sightpath to Deliver IQity’s Products Through Mobile Platform Under New Partnership

Reno, Nevada-based IQity reported May 21 that it was partnering with Sightpath Medical to deliver its technology to surgeons. IQity is developing eight products expected to launch between 2027 and ...

Luminopia Licenses Amblyopia Therapy to Rohto for Japan Market
Luminopia Licenses Amblyopia Therapy to Rohto for Japan Market

Luminopia, of Cambridge, Massachusetts, reported June 2 that it had licensed its pediatric amblyopia treatmentto Rohto Pharmaceutical Co. to develop and commercialize in Japan. Rohto is a Japanese ...

US FDA Leadership Shakeup Continues as Drug Division Chief Exits
US FDA Leadership Shakeup Continues as Drug Division Chief Exits

The US FDA’s drug evaluation division has another new leader. Michael Davis, MD, PhD, has been named acting director of the Center for Drug Evaluation and Research (CDER), according to the FDA’s we...

Georgia Southern University Gains Funding for State’s First College of Optometry
Georgia Southern University Gains Funding for State’s First College of Optometry

Georgia Southern University announced May 26 that it had received $29.8 million in state funding to establish the first college of optometry in Georgia. The school said the money will support the r...

SpyGlass Gains Category III CPT Code for Its Drug-Eluting BIM-IOL System
SpyGlass Gains Category III CPT Code for Its Drug-Eluting BIM-IOL System

SpyGlass Pharma, of Aliso Viejo, California, reported May 18 that the American Medical Association had approved a new add-on Category III CPT code that will allow surgeons to be reimbursed separate...

Carl Zeiss Meditec Names Bronwyn Brophy O’Connor as CEO
Carl Zeiss Meditec Names Bronwyn Brophy O’Connor as CEO

German company Carl Zeiss Meditec reported May 22 that it had appointed Bronwyn Brophy O’Connor as chief executive officer and a member of the management board. Zeiss said O’Connor brings 25 years ...

Q1-2026 Ophthalmic Revenue Roundup for Apellis, Immunocore, STAAR, and Iridex
Q1-2026 Ophthalmic Revenue Roundup for Apellis, Immunocore, STAAR, and Iridex

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 in its quarterly financial report for Q1-2026 that its net product revenue for Syfovre was $150.7 million, a 15.4 percent increase...

Myopia Management Roundup: Research Includes Study Raising Safety Concerns over Some Red-Light Devices
Myopia Management Roundup: Research Includes Study Raising Safety Concerns over Some Red-Light Devices

A laboratory study published this year in JAMA Ophthalmology calls into question the safety of commercially available red-light therapy devices as a treatment option for young myopes. Repeated low-...

Study Links Vitamins B3 and B12 to Lower Risk of Glaucoma
Study Links Vitamins B3 and B12 to Lower Risk of Glaucoma

Researchers in the Netherlands recently assessed the link between B vitamin intake and glaucoma. Their findings were published in April in the American Journal of Ophthalmology. B vitamins play an ...

ViaLase Announces First Commercial FLIGHT Procedures in Glaucoma Patients
ViaLase Announces First Commercial FLIGHT Procedures in Glaucoma Patients

ViaLase, of Aliso Viejo, California, announced May 26 that surgeons in London and Germany had performed the first commercial procedures using its ViaLuxe Laser System for femtosecond laser image-gu...

Patients Satisfied with Same-Day Bilateral Cataract Surgery, Study Finds
Patients Satisfied with Same-Day Bilateral Cataract Surgery, Study Finds

Danish researchers who interviewed same-day bilateral cataract surgery patients found that the patients appreciated the convenience and welcomed empathetic communication before, during, and after t...

Video Series from World Council of Optometry and Alcon Summarizes TFOS DEWS III
Video Series from World Council of Optometry and Alcon Summarizes TFOS DEWS III

The World Council of Optometry (WCO) and Alcon have released a series of three videos to help eye care professionals understand and apply recommendations from the updated Dry Eye Workshop III (DEWS...

US FDA Signs Off on Special Protocol Assessment for Oculis’ Optic Neuritis Trial
US FDA Signs Off on Special Protocol Assessment for Oculis’ Optic Neuritis Trial

Swiss company Oculis announced May 7 that the US FDA had agreed to a special protocol assessment regarding PIONEER-1, a Phase III clinical trial evaluating Privosegtor for the treatment of optic ne...

Annual and Quarterly Ophthalmic Revenue Roundup for Santen, Carl Zeiss Meditec, Harrow, RxSight, ANI, and Lensar
Annual and Quarterly Ophthalmic Revenue Roundup for Santen, Carl Zeiss Meditec, Harrow, RxSight, ANI, and Lensar

Japan-based Santen reported May 12 that its revenue for its fiscal year 2025, which ended March 31, 2026, was JPY 291.6 billion ($1.8 billion, calculated for March 31, 2026), a 2.8 percent decline ...

Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US
Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US

Bausch + Lomb reported May 19 that it had launched its PreserVision AREDS3 eye vitamins in the US. The supplements add a unique B-vitamin complex to the AREDS2 nutrients recommended by the National...

Myopia Management Roundup: SightGlass, Hoya Tout Positive Results with Spectacle Lenses
Myopia Management Roundup: SightGlass, Hoya Tout Positive Results with Spectacle Lenses

SightGlass Vision reported May 6 that its DOT spectacle lenses for myopia control saved more than 1 diopter of progression on average after two years in a study of Chinese children ages 6 to 10. Th...

Portuguese Study of Luxturna Shows Functional Benefits, Structural Decline
Portuguese Study of Luxturna Shows Functional Benefits, Structural Decline

Luxturna (voretigene neparvovec) has demonstrated in clinical trials and real-world studies that it improves light sensitivity and functional vision, with a favorable safety profile. A new prospect...

Curative to Advance Metformin Eye Drops in Cooperation with PennVet
Curative to Advance Metformin Eye Drops in Cooperation with PennVet

Curative Biotechnology announced May 7 that it had entered into a sponsored research agreement with the University of Pennsylvania’s School of Veterinary Medicine (PennVet) to support a canine stud...

AOA Honors Leaders in Optometry With 2026 Annual Awards
AOA Honors Leaders in Optometry With 2026 Annual Awards

The American Optometric Association (AOA), the American Optometric Student Association, and the AOA Foundation have announced the recipients of the organizations’ 2026 annual awards. The winners ar...

Generics, New Drug Classes, Sustained Release Dosing Shape Glaucoma Pharma Market
Generics, New Drug Classes, Sustained Release Dosing Shape Glaucoma Pharma Market

The glaucoma pharmaceuticals market is showing signs of emerging from its prolonged revenue slump. One cycle of conversions from proprietary drugs to generic drugs is nearing an end, and a new cycl...

Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz
Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz

Tarsus Pharmaceuticals, of Irvine, California, reported May 6 that its Q1-2026 revenue for Xdemvy was $145.4 million, an 85 percent increase over $78.3 million in Q1-2025. Xdemvy (lotilaner ophthal...

US FDA Commissioner Makary Resigns After Rocky Year in Top Job
US FDA Commissioner Makary Resigns After Rocky Year in Top Job

US FDA Commissioner Marty Makary, MD, MPH, resigned May 12 after a rocky year in the agency’s top job that saw mass layoffs, high-level resignations, and policy fights with lawmakers, drugmakers, a...

AMA Urges Physician Protections Against AI Deepfake Impersonation
AMA Urges Physician Protections Against AI Deepfake Impersonation

The American Medical Association (AMA) in April issued a policy framework that it says aims to combat the escalating risk of AI-manipulated images, videos, and audio that impersonate physicians. Th...

Mexico Approves Zeiss’ Artevo 850 OR Microscope and Micor 700 Cataract Handpiece
Mexico Approves Zeiss’ Artevo 850 OR Microscope and Micor 700 Cataract Handpiece

Carl Zeiss Meditec announced May 13 that regulators in Mexico had approved the Artevo 850 ophthalmic microscope and the Micor 700 cataract removal handpiece. The German company, with US headquarter...

IOP-Lowering Goggles Gain US FDA 510(k) Nod for Wireless Upgrade
IOP-Lowering Goggles Gain US FDA 510(k) Nod for Wireless Upgrade

Balance Ophthalmics announced May 12 that it had gained US FDA 510(k) clearance for a wireless-enabled, next-generation version of its FSYX Ocular Pressure Adjusting Pump (FSYX OPAP) system, design...

NeuroVision Acquires Durin Life Sciences to Advance Neurological Diagnostics
NeuroVision Acquires Durin Life Sciences to Advance Neurological Diagnostics

NeuroVision, the developer of Afina retinal imaging technology to detect neurodegenerative disease, announced May 12 that it had acquired Durin Life Sciences, of Stratford, New Jersey. No financial...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more